Literature DB >> 22753945

Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent.

Manu Vanaerschot1, Saskia Decuypere, Tim Downing, Hideo Imamura, Olivia Stark, Simonne De Doncker, Syamal Roy, Bart Ostyn, Louis Maes, Basudha Khanal, Marleen Boelaert, Gabriele Schönian, Matthew Berriman, François Chappuis, Jean-Claude Dujardin, Shyam Sundar, Suman Rijal.   

Abstract

The current standard to assess pentavalent antimonial (SSG) susceptibility of Leishmania is a laborious in vitro assay of which the result has little clinical value because SSG-resistant parasites are also found in SSG-cured patients. Candidate genetic markers for clinically relevant SSG-resistant parasites identified by full genome sequencing were here validated on a larger set of clinical strains. We show that 3 genomic locations suffice to specifically detect the SSG-resistant parasites found only in patients experiencing SSG treatment failure. This finding allows the development of rapid assays to monitor the emergence and spread of clinically relevant SSG-resistant Leishmania parasites.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22753945      PMCID： PMC4125624          DOI： 10.1093/infdis/jis424

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal.

Authors:  Thierry Laurent; Suman Rijal; Vanessa Yardley; Simon Croft; Simonne De Doncker; Saskia Decuypere; Basudha Khanal; Rupa Singh; Gabriele Schönian; Katrin Kuhls; François Chappuis; Jean-Claude Dujardin
Journal:  Infect Genet Evol       Date:  2006-09-27       Impact factor: 3.342

2.  Antigenic variation in syringe passaged populations of Trypanosoma (Trypanozoon) brucei. 1. Rationalization of the experimental approach.

Authors:  N Van Meirvenne; P G Janssens; E Magnus
Journal:  Ann Soc Belg Med Trop       Date:  1975

Review 3.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

Authors:  François Chappuis; Shyam Sundar; Asrat Hailu; Hashim Ghalib; Suman Rijal; Rosanna W Peeling; Jorge Alvar; Marleen Boelaert
Journal:  Nat Rev Microbiol       Date:  2007-11       Impact factor: 60.633

4.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

Authors:  R Lira; S Sundar; A Makharia; R Kenney; A Gam; E Saraiva; D Sacks
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

5.  Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance.

Authors:  Tim Downing; Hideo Imamura; Saskia Decuypere; Taane G Clark; Graham H Coombs; James A Cotton; James D Hilley; Simonne de Doncker; Ilse Maes; Jeremy C Mottram; Mike A Quail; Suman Rijal; Mandy Sanders; Gabriele Schönian; Olivia Stark; Shyam Sundar; Manu Vanaerschot; Christiane Hertz-Fowler; Jean-Claude Dujardin; Matthew Berriman
Journal:  Genome Res       Date:  2011-10-28       Impact factor: 9.043

Review 6.  Leishmania antimony resistance: what we know what we can learn from the field.

Authors:  Khatima Aït-Oudhia; Elodie Gazanion; Baptiste Vergnes; Bruno Oury; Denis Sereno
Journal:  Parasitol Res       Date:  2011-07-29       Impact factor: 2.289

7.  Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?

Authors:  Suman Rijal; Vanessa Yardley; François Chappuis; Saskia Decuypere; Basudha Khanal; Rupa Singh; Marleen Boelaert; Simonne De Doncker; Simon Croft; Jean-Claude Dujardin
Journal:  Microbes Infect       Date:  2007-01-27       Impact factor: 2.700

8.  Linking in vitro and in vivo survival of clinical Leishmania donovani strains.

Authors:  Manu Vanaerschot; Ilse Maes; Meriem Ouakad; Vanessa Adaui; Louis Maes; Simonne De Doncker; Suman Rijal; François Chappuis; Jean-Claude Dujardin; Saskia Decuypere
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

9.  Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

Authors:  S Rijal; F Chappuis; R Singh; P A Bovier; P Acharya; B M S Karki; M L Das; P Desjeux; L Loutan; S Koirala
Journal:  Trans R Soc Trop Med Hyg       Date:  2003 May-Jun       Impact factor: 2.184

10.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08
View more
  12 in total

Review 1.  Species typing in dermal leishmaniasis.

Authors:  Gert Van der Auwera; Jean-Claude Dujardin
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

2.  Preclinical Studies Evaluating Subacute Toxicity and Therapeutic Efficacy of LQB-118 in Experimental Visceral Leishmaniasis.

Authors:  Edézio Ferreira Cunha-Júnior; Thiago Martino Martins; Marilene Marcuzzo Canto-Cavalheiro; Paulo Roberto Marques; Elyzabeth Avvad Portari; Marsen Garcia Pinto Coelho; Chaquip Daher Netto; Paulo Roberto Ribeiro Costa; Katia Costa de Carvalho Sabino; Eduardo Caio Torres-Santos
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

3.  A Multiplatform Metabolomic Approach to the Basis of Antimonial Action and Resistance in Leishmania infantum.

Authors:  David Rojo; Gisele A B Canuto; Emerson A Castilho-Martins; Marina F M Tavares; Coral Barbas; Ángeles López-Gonzálvez; Luis Rivas
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

Review 4.  Drug resistance analysis by next generation sequencing in Leishmania.

Authors:  Philippe Leprohon; Christopher Fernandez-Prada; Élodie Gazanion; Rubens Monte-Neto; Marc Ouellette
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-09-22       Impact factor: 4.077

5.  Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.

Authors:  Sarah Hendrickx; Annelies Leemans; Annelies Mondelaers; Suman Rijal; Basudha Khanal; Jean-Claude Dujardin; Peter Delputte; Paul Cos; Louis Maes
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 6.  Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance.

Authors:  Marie-Claude N Laffitte; Philippe Leprohon; Barbara Papadopoulou; Marc Ouellette
Journal:  F1000Res       Date:  2016-09-20

7.  Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 Production.

Authors:  Emebet Adem; Fitsumbirhan Tajebe; Mulusew Getahun; Amare Kiflie; Ermias Diro; Asrat Hailu; Ziv Shkedy; Bewketu Mengesha; Tadele Mulaw; Saba Atnafu; Tekalign Deressa; Biniam Mathewos; Ebba Abate; Manuel Modolell; Markus Munder; Ingrid Müller; Yegnasew Takele; Pascale Kropf
Journal:  PLoS Negl Trop Dis       Date:  2016-03-10

Review 8.  Evaluating drug resistance in visceral leishmaniasis: the challenges.

Authors:  S Hendrickx; P J Guerin; G Caljon; S L Croft; L Maes
Journal:  Parasitology       Date:  2016-11-21       Impact factor: 3.234

Review 9.  Strategies to overcome antileishmanial drugs unresponsiveness.

Authors:  Shyam Sundar; Anup Singh; Om Prakash Singh
Journal:  J Trop Med       Date:  2014-04-30

10.  Antimony resistant Leishmania donovani but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF-β in early immune response.

Authors:  Rajan Guha; Shantanabha Das; June Ghosh; Shyam Sundar; Jean Claude Dujardin; Syamal Roy
Journal:  PLoS Negl Trop Dis       Date:  2014-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.